| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3946539 | Gynecologic Oncology | 2007 | 6 Pages |
Abstract
A 28-day schedule of oxaliplatin and topotecan is safe and well tolerated. Because of the in vitro synergy observed between topoisomerase I inhibitors and platinum derivatives and the tolerability reported in the current study, this regimen warrants further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
John C. Elkas, William E. III, Mildred R. Chernofsky, Jan Sunde, Michael A. Bidus, Sarah Bernstein, G. Scott Rose,